Drug Type Fab fragment |
Synonyms Anti-PcrV mAb fragment, KB-001, KB-001A |
Target |
Action inhibitors |
Mechanism T3SS inhibitors(Type III secretion system protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystic Fibrosis | Phase 2 | United States | 01 Dec 2012 | |
Cystic Fibrosis | Phase 2 | Australia | 01 Dec 2012 | |
Cystic Fibrosis | Phase 2 | Israel | 01 Dec 2012 | |
Cystic Fibrosis | Phase 2 | New Zealand | 01 Dec 2012 | |
Pneumonia, Ventilator-Associated | Phase 2 | France | 01 Apr 2008 | |
Pseudomonas aeruginosa infection | Phase 2 | United States | 01 Mar 2008 |
Phase 2 | 169 | ctgkbqozxk(hspdaonzzl) = Time to need for antibiotics did not differ between groups vssyihawee (ymuujketmt ) View more | Positive | 01 Jul 2018 | |||
Placebo |